Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | POLD1 | P28340 | 1/20 | 0.60 |
| ▸ | TK1 | P04183 | 5/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26757239 | 0.94 | TK1 (0.55) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL14279195 | 0.94 | TK1 (0.55) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL11984465 | 0.93 | POLB (0.57) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL265387 | 0.93 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL18855348 | 0.93 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL30586988 | 0.93 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL77582 | 0.93 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL3031874 | 0.93 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL154177 | 0.91 | POLB (0.65) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL19389391 | 0.90 | POLB (0.49) | POLBPOLA1POLD1TK1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20100216122-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS | Life Technologies Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | POLB 16/4885POLA1 41/4885POLD1 86/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | POLB 16/4885POLA1 23/4885POLD1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.